Organon Selling And Marketing Expenses vs Net Income Analysis
OGN Stock | USD 15.68 0.56 3.70% |
Organon financial indicator trend analysis is much more than just breaking down Organon prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Organon is a good investment. Please check the relationship between Organon Selling And Marketing Expenses and its Net Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Selling And Marketing Expenses vs Net Income
Selling And Marketing Expenses vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Organon Selling And Marketing Expenses account and Net Income. At this time, the significance of the direction appears to have very week relationship.
The correlation between Organon's Selling And Marketing Expenses and Net Income is 0.29. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Net Income in the same time period over historical financial statements of Organon Co, assuming nothing else is changed. The correlation between historical values of Organon's Selling And Marketing Expenses and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Organon Co are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Selling And Marketing Expenses i.e., Organon's Selling And Marketing Expenses and Net Income go up and down completely randomly.
Correlation Coefficient | 0.29 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Selling And Marketing Expenses
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Organon financial statement analysis. It represents the amount of money remaining after all of Organon Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Organon's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Organon current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. As of the 12th of December 2024, Tax Provision is likely to drop to about 90.2 M. In addition to that, Selling General Administrative is likely to drop to about 1.3 B
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 258M | 422M | 527M | 553.4M | Tax Provision | 178M | 205M | 95M | 90.3M |
Organon fundamental ratios Correlations
Click cells to compare fundamentals
Organon Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Organon fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.5B | 10.4B | 10.7B | 11.0B | 12.1B | 11.9B | |
Short Long Term Debt Total | 104M | 31M | 9.1B | 8.9B | 8.8B | 4.9B | |
Other Current Liab | 1.0B | 2.3B | 1.0B | 1.2B | 1.4B | 1.3B | |
Total Current Liabilities | 1.3B | 1.2B | 2.6B | 2.5B | 2.9B | 2.2B | |
Total Stockholder Equity | 7.0B | (820M) | (1.5B) | (892M) | (70M) | (66.5M) | |
Other Liab | 2.0B | 1.9B | 283M | 280M | 252M | 239.4M | |
Net Tangible Assets | 1.9B | 380M | (6.9B) | (6.1B) | (5.5B) | (5.3B) | |
Accounts Payable | 258M | 259M | 1.4B | 1.1B | 1.3B | 849.6M | |
Cash | 319M | 500M | 737M | 706M | 693M | 586.5M | |
Other Assets | 659M | 347M | 464M | 539M | 485.1M | 435.7M | |
Long Term Debt | 70M | 0.0 | 9.1B | 8.9B | 8.8B | 4.9B | |
Cash And Short Term Investments | 319M | 500M | 737M | 706M | 693M | 586.5M | |
Net Receivables | 1.5B | 1.1B | 1.4B | 1.5B | 1.7B | 1.6B | |
Long Term Debt Total | 70M | 0.0 | 9.1B | 8.9B | 10.2B | 10.8B | |
Liabilities And Stockholders Equity | 10.5B | 10.4B | 10.7B | 11.0B | 12.1B | 11.9B | |
Inventory | 1.1B | 913M | 915M | 1.0B | 1.3B | 1.1B | |
Other Current Assets | 1.1B | 1.6B | 726M | 747M | 756M | 764M | |
Other Stockholder Equity | 7.9B | 216M | (513M) | (564M) | 25M | 23.8M | |
Total Liab | 3.5B | 11.3B | 12.2B | 11.8B | 12.1B | 10.1B | |
Total Current Assets | 4.0B | 3.4B | 3.8B | 3.9B | 4.5B | 4.3B | |
Cash And Equivalents | 319M | 12M | 737M | 706M | 811.9M | 444.0M | |
Intangible Assets | 569M | 503M | 651M | 649M | 533M | 495.6M | |
Property Plant Equipment | 762M | 1.1B | 973M | 1.2B | 1.4B | 1.0B |
Pair Trading with Organon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will appreciate offsetting losses from the drop in the long position's value.Moving together with Organon Stock
Moving against Organon Stock
0.93 | BMY | Bristol Myers Squibb | PairCorr |
0.84 | GILD | Gilead Sciences | PairCorr |
0.78 | CAH | Cardinal Health | PairCorr |
0.74 | ESPR | Esperion Therapeutics | PairCorr |
0.64 | XAIR | Beyond Air | PairCorr |
The ability to find closely correlated positions to Organon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organon Co to buy it.
The correlation of Organon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.